Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR

Hypertension

Volumn 29, Issue 1 II, 1997, Pages 519-524

  Nunez, Eduardo ^a   Hosoya, Kazuyoshi ^a   Susic, Dinko ^a   Frohlich, Edward D ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

angiotensin II antagonism and inhibition ; coronary circulation; drug synergism; enalapril; left ventricular hypertrophy reversal ; losartan; spontaneously hypertensive rats

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENALAPRIL; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY HEMODYNAMICS; CORONARY VASCULAR RESISTANCE; DOSE RESPONSE; DRUG MIXTURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0031028695     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.29.1.519     Document Type: Article

References (48)

1. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham Heart Study. Ann Intern Med. 1970;72: 813-822.
2. Casale PN, Devereaux RB, Milner M, Zullo G, Harschfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173-178.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
4. Susie D, Nunez E, Frohlich ED, Reversal of hypertrophy: an active biologic process. Curr Opin Cardiol. 1995;10:466-472.
5. Marcus ML, Mueller TM, Gascho JA, Kerber RE. Effect of cardiac hypertrophy secondary to hypertension on the coronary circulation. Am J Cardiol. 1979;44:1023-1028.
6. Sato F, Isoyama S, Takishima T. Normalization of impaired coronary circulation in hypertrophied rat hearts. Hypertension. 1990;16:26-34.
7. Pichard AD, Frolin R, Smith H, Ambrose J, Meller J. Coronary flow studies in patients with left ventricular hypertrophy of the hypertensive type: evidence for an impaired coronary vascular reserve. Am J Cardiol. 1981;47:547-554.
8. Opherk D, Mall G, Zebe H, Schwartz F, Weihe E, Manthey J, Kübler W. Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation. 1984;69:1-7.
9. Motz W, Strauer BE. Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension. 1996;27:1031-1038.
10. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D, Shub C. The heart in hypertension. N Engl J Med. 1992;327:998-1008.
11. Soria F, Frohlich ED, Aristizabal D, Kaneko K, Kardon MB, Hunter J, Pegram BL. Preserved cardiac performance after quinapril-induced left ventricular mass reversal in spontaneously hypertensive rats. J Hypertens. 1994;12:585-589.
12. Ishise S, Pegram BL, Yamamoto J, Kitamura Y, Frohlich ED. Reference sample microsphere method: cardiac output and blood flows in conscious rat. Am J Physiol. 1980;239:H443-H449.
13. Kaneko K, Susie D, Nunez E, Frohlich ED. Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat. J Hypertens. 1996;14:645-653.
14. Pfeffer MA, Pfeffer JM, Dunn FG, Nishiyama K, Tsuchiya M, Frohich ED. Natural biventricular hypertrophy in normotensive rats, I: physical and hemodynamic characteristics. Am J Physiol. 1973;236: H640-H643.
15. Sesoko S, Pegram BL, Kuwajima I, Frohlich ED. Hemodynamic studies in spontaneously hypertensive rats with congenital arteriovenous shunts. Am J Physiol. 1982;242:H722-H725.
16. Chilian WM, Wangler RD, Peters KG, Tomanek RJ, Marcus ML. Thyroxine induced left ventricular hypertrophy in the rat: anatomical and physiological evidence for angiogenesis. Circ Res. 1985;57: 591-598.
17. Armitage P, Berry G. Statistical Methods in Medical Research. 3rd ed. Oxford, UK: Blackwell Scientific Publications; 1994.
18. Frison L, Pocock SJ, Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med. 1992;11:1685-1704.
19. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res. 1994;28:303-311.
20. Frohlich ED, Horinaka S. Cardiac and aortic effects of angiotensin converting enzyme inhibitors. Hypertension. 1991;18(suppl II): II-2-II-7.
21. Frohlich ED, Sasaki O. Dissociation of changes in cardiovascular mass and performance in angiotensin converting enzyme inhibitor in Wistar-Kyoto and spontaneously hypertensive rats. J Am Coll Cardiol. 1990;16:1492-1499.
22. Ando K, Frohlich ED, Chien Y, Pegram BL. Effects of quinapril on systemic and regional hemodynamics and cardiac mass in spontaneously hypertensive and Wistar-Kyoto rats. J Vasc Med Biol. 1991;3:117-123.
23. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation. 1991;83:13-26.
24. Zierhut W, Zimmer HG, Gerdes AM. Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats. Circ Res. 1991;69:609-617.
25. Tarazi RC, Frohlich ED. Is reversal of cardiac hypertrophy a desirable goal of antihypertensive therapy? Circulation. 1987;75(suppl I): I-113-I-117.
26. Frohlich ED. Overview of hemodynamic and non-hemodynamic factors associated with LVH. J Mol Cell Cardiol. 1989;21:3-10.
27. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation. 1994;89:493-498.
28. Wiemer G, Schölkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991;18:558-563.
29. Cachofeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension. 1992;19:138-145.
30. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin-converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension. 1994;23:411-418.
31. Scicli AG. Increases in cardiac kinins as a new mechanism to protect the heart. Hypertension. 1994;23:419-421.
32. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
33. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens. 1993;11(suppl 3):13-18.
34. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research? J Hypertens. 1994; 12(suppl 2):1-5.
35. Arita M, Horinaka S, Frohlich ED. Biochemical components and myocardial performance after reversal of left ventricular hypertrophy in spontaneously hypertensive rats. J Hypertens. 1993;11:951-959.
36. Arita M, Horinaka S, Komatsu K, Frohlich ED. Reversal of left ventricular hypertrophy with different classes of drugs causes differing ventricular biochemical changes. J Hypertens. 1993;11:S354-S355.
37. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347-467.
38. Motz W, Strauer BE. Regression of structural cardiovascular changes by antihypertensive therapy. Hypertension. 1984;6(suppl III): III-133-III-139.
39. Tomanek RJ, Palmer PY, Pfeiffer GL, et al. Morphometry of canine coronary arteries, arterioles and capillaries during hypertension and left ventricular hypertrophy. Circ Res. 1986;58:38-46.
40. Anderson PG, Bishop SP, Digerness SB. Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats. Circ Res. 1989;64:1127-1136.
41. Schwartzkopff B, Motz W, Knauer S, Frenzel H, Strauer BE. Morphometric investigation of intramyocardial arterioles in right septal endomyocardial biopsy of patients with arterial hypertension and left ventricular hypertrophy. J Cardiovasc Pharmacol. 1992;20(suppl 1):S12-S17.
42. Nitenberg A, Antony I. Epicardial coronary arteries are not adequately sized in hypertensive patients. J Am Coll Cardiol. 1996;27:115-123.
43. Bossaller C, Auch-Schwelk W, Weber F, Götze S, Gräfe M, Graf K, Fleck E. Endothelium-dependent relaxation are augmented in rats chronically treated with the angiotensin-converting enzyme inhibitor enalapril. J Cardiovas Pharmacol. 1992;20(suppl 9):S91-S95.
44. Kelm M, Feelisch M, Krebber T, DeuBen A, Motz W, Strauer BE. Role of nitric oxide in the regulation of coronary vascular tone in hearts from hypertensive rats: maintenance of nitric oxide-forming capacity and increased basal production of nitric oxide. Hypertension. 1995;25:186-193.
45. Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Uischer TF. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation. 1994;89:2212-2218.
46. Tschudi MR, Lüscher TF. Age and hypertension differently affect coronary contractions to endothelin-1, serotonin, and angiotensins. Circulation. 1995;91:2415-2422.
47. Sato F, Isoyama S, Takishima T. Normalization of impaired coronary circulation in hypertrophied rat hearts. Hypertension. 1990;16:26-34.
48. Clozel JP, Veniant M, Hess P, Sprecher U. Effects of two angiotensin converting enzyme inhibitors and hydralazine on coronary circulation in hypertensive rats. Hypertension. 1991;18(suppl II):II-8-II-14.